A phase I/II trial to investigate the safety and efficacy of rituximab and intravenous immunoglobulin (IVIG) as agents to desensitize highly human leukocyte antigen (HLA) sensitized dialysis patients awaiting kidney transplantation

Trial Profile

A phase I/II trial to investigate the safety and efficacy of rituximab and intravenous immunoglobulin (IVIG) as agents to desensitize highly human leukocyte antigen (HLA) sensitized dialysis patients awaiting kidney transplantation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Immune globulin (Primary) ; Rituximab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jul 2008 Results have been published in the New England Journal of Medicine.
    • 10 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top